PF
Phil Ferneau
Investor at Ankyra Therapeutics
PF
Phil Ferneau
Investor at Ankyra Therapeutics
Hanover, New Hampshire
Overview
Work Experience
Co-Founder and Managing Partner
2002 - Current
Early-stage healthcare venture capital firm, with a focus on life science platforms, digital health, and animal health opportunities.
Board Director and Investor
2014
Antibody therapeutics to treat cancer (Nasdaq: CMPX)
Board Director and Investor
2021
Intratumoral immunotherapy.
Investor and Former Board Director
2020
Genetics-informed antibody therapies for I&I disorders.
Board Director and Investor
2019
Redefining the role of genomic laboratories in delivering better healthcare.
Investor and Former Board Director
2020
Platform company developing novel TCR therapies for cancer and autoimmune disease.
Board Director and Investor
2018
Peptide discovery platform company spun out from the University of Oxford
Board Observer and Investor
2018
The future of clinical research.
Investor
2008
Premier human antibody discovery and humanization.
Investor
2018
Transformative exosome therapeutics.